Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Raised to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) from a hold rating to a buy rating in a report released on Friday morning.

Separately, Hsbc Global Res raised shares of Bayer Aktiengesellschaft to a “hold” rating in a research note on Monday, April 28th.

Bayer Aktiengesellschaft Stock Performance

OTCMKTS:BAYRY opened at $7.59 on Friday. The company has a quick ratio of 0.81, a current ratio of 1.32 and a debt-to-equity ratio of 1.19. The firm’s fifty day simple moving average is $6.45 and its 200 day simple moving average is $5.87. The stock has a market cap of $29.83 billion, a P/E ratio of -29.19 and a beta of 0.85. Bayer Aktiengesellschaft has a twelve month low of $4.79 and a twelve month high of $8.58.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its quarterly earnings data on Tuesday, May 13th. The company reported $0.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.63 by $0.02. The business had revenue of $15.27 billion during the quarter, compared to the consensus estimate of $13.39 billion. Bayer Aktiengesellschaft had a positive return on equity of 16.90% and a negative net margin of 2.02%. As a group, research analysts predict that Bayer Aktiengesellschaft will post 1.31 EPS for the current year.

Bayer Aktiengesellschaft Increases Dividend

The business also recently announced a dividend, which was paid on Monday, May 12th. Shareholders of record on Wednesday, April 30th were issued a $0.0224 dividend. This represents a yield of 0.38%. This is an increase from Bayer Aktiengesellschaft’s previous dividend of $0.02. The ex-dividend date was Tuesday, April 29th. Bayer Aktiengesellschaft’s payout ratio is -2.17%.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.